Lonza’s Post

Simon Wagschal talks about the evolving landscape of API and drug substance development and a trend towards longer synthetic routes. Read our recent R&D blog about a route scouting solution for these increasingly complex molecules, which combines AI-driven retrosynthetic analysis with the technical knowledge and experience of our experts. https://lnkd.in/erKxD8b7 #AHealthierWorld #Innovation #PharmaceuticalManufacturing #AI #SmallMolecules

Lonza is excited to attend Bioplus-Interphex Korea 2024 next week as a gold sponsor. Our colleagues from Biologics, Small Molecules and Cell & Gene will be available to discuss ways they can support your complex needs in drug development and manufacturing. On Wednesday 10th, Dr Yvette Stallwood will give an insightful presentation on how to navigate the road to first-in-human clinical trials: 📅 Wednesday, 10 July 🕝 1.20pm ⭐Optimising the Path to First-in-Human Clinical Trials: An Integrated Approach to Design and De-risk Your Candidate, Including ADCs Speaker: Yvette Stallwood, Head of Early Development Services You can meet us at Booth #M31 - we are excited to see you there #Lonza #LonzaBIO #LonzaSM #LonzaCGT #AHealthierWorld

Today, Wolfgang Wienand joins Lonza as our CEO. A proven leader, he brings a wealth of expertise and experience from almost two decades in senior leadership positions in the CDMO industry. We are looking forward to working with Wolfgang to meet and exceed the needs of our customers and their patients as we pursue our purpose to enable a healthier world.

Earlier this month, we experienced an incredible few days connecting with you at BIO International. We participated in engaging and insightful discussions, and thank everyone who connected with our team onsite in San Diego. We enjoyed meeting you at our booth, networking with you at our evening reception, and learning more about your biologics, cell and gene therapy and small molecule needs.   We look forward to further collaborating to drive positive change in our industry. See you in Boston in 2025! #BIO2024 #biologics #celltherapy #genetherapy #smallmolecules

At Lonza, Pride Month is our opportunity to recognize and celebrate the immense value that our diverse colleagues bring to our business. But for us, Pride is more than a month. We are working all the time to create a culture of inclusion and affirmation in which every colleague is safe and supported to be themselves and bring their best. This is how we make a meaningful difference together. #Lonza #PrideMonth #AMeaningfulDifference

Join our Lonza experts James Berrie and Eddy BERTHIER for an upcoming webinar, where they will explore innovative strategies and good practices to accelerate the pathway into clinical development for novel biotherapeutics. This session will delve into comprehensive and integrated drug substance/drug product DNA-to-IND programs designed to expedite development across various modalities, including monoclonal antibodies, bispecific antibodies, Fabs, Fc-fusions and non-Fc recombinant proteins. Register today: https://lnkd.in/e2F8X259 📅 Monday, 8 July 🕝 11am EDT / 5pm CET #Lonza #Biologics

Join us for a must-see webinar on the critical aspects of technology transfer of either biological drug substance or drug product. This session will delve into the strategies and best practices for seamless tech transfer processes, ensuring regulatory compliance, and maintaining product quality and consistency. We will explore real-world case studies highlighting innovative solutions to accelerate clinical tech transfer for drug products, enabling a released clinical batch within five months from kick-off. 📅 Thursday, 11 July, 2024 🕚 11am EDT / 5pm CET Register today: https://lnkd.in/engVg32Y Featured experts: Maolong Liu, Angela Armanni, Andrea Lei Leston #techTransfers #LonzaDPS #sterileDrugProduct #parenteralDrugProduct #drugProduct

We are pleased to share the June edition of Biologics In Focus, the biologics newsletter from Lonza. Each month we deliver deep analysis of industry trends, expert insights, and an overview of upcoming events - as well as the latest Lonza news and real world customer stories. This month's highlights include: -A webinar from early June on navigating a holistic approach to Container Closure Integrity for biologic drug products -An article from BioPharm International where Lonza experts talk about technological advances that are impacting current aseptic processes and improving time-to-market -A real customer case study from Levicept, discussing their experience with Lonza and how they built a strong relationship to deliver successful partnership outcomes Please do subscribe to ensure you receive the future editions of Biologics In Focus #LonzaBio #pharma #biotechnology #thePeoplePoweringBiologics

"The complexity of drugs and their delivery has been increasing over the past few decades. Combined with a growing prevalence of chronic illnesses, this market evolution is putting more pressure on pharmaceutical manufacturers to develop novel therapies that might also have unique formulation needs.” Peter Droc, Head of Drug Product Services at Lonza, recently shared his thoughts on the solutions to increasingly complex formulation needs, and how these can ensure quality and patient safety, while also decreasing time-to-market. Belinda Holdsworth, Strategic Growth Project Lead for DPS at Lonza, also emphasized how a robust visual inspection process which utilizes AI and automated robotics can greatly enhance process timelines. Read the full article here: https://lnkd.in/eds3Xnkw #AHealthierWorld #DrugProduct #LonzaDPS